

The authors reply

We appreciate the comments from Riechelmann and Krzyzanowska on our manuscript. Owing to space limitations we were unable to address the epidemiology of drug interactions in patients with cancer, and welcome the addition of their data in the follow-up letter. Clearly this field of research is still in the early stages, and continued investigation is warranted to document the effect of drug interactions on patient safety.

Charity D. Scripture and William D. Figg

Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, MSC1910, Bethesda, MD 20892, USA.